IN2015MN00421A - - Google Patents

Info

Publication number
IN2015MN00421A
IN2015MN00421A IN421MUN2015A IN2015MN00421A IN 2015MN00421 A IN2015MN00421 A IN 2015MN00421A IN 421MUN2015 A IN421MUN2015 A IN 421MUN2015A IN 2015MN00421 A IN2015MN00421 A IN 2015MN00421A
Authority
IN
India
Prior art keywords
casr
compounds
lessening
syndromes
severity
Prior art date
Application number
Other languages
English (en)
Inventor
Manojkumar Ramprasad Shukla
Vinod Dinkar Chaudhari
Ankush Gangaram Sarde
Ramesh Dattatraya Phadtare
Mahadeo Bhaskar Tryambake
Dronamraju Prameela
Sanjeev Anant Kulkarni
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN421MUN2015 priority Critical patent/IN2015MN00421A/en
Publication of IN2015MN00421A publication Critical patent/IN2015MN00421A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
IN421MUN2015 2012-08-27 2013-08-23 IN2015MN00421A (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN421MUN2015 IN2015MN00421A (enExample) 2012-08-27 2013-08-23

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN988KO2012 2012-08-27
IN1031KO2012 2012-09-10
IN421MUN2015 IN2015MN00421A (enExample) 2012-08-27 2013-08-23
PCT/IB2013/056840 WO2014033604A1 (en) 2012-08-27 2013-08-23 Arylalkylamine compounds as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
IN2015MN00421A true IN2015MN00421A (enExample) 2015-09-04

Family

ID=54203597

Family Applications (1)

Application Number Title Priority Date Filing Date
IN421MUN2015 IN2015MN00421A (enExample) 2012-08-27 2013-08-23

Country Status (10)

Country Link
US (3) US9227919B2 (enExample)
EP (1) EP2888225A1 (enExample)
JP (1) JP2015528462A (enExample)
CN (1) CN104583177B (enExample)
AU (1) AU2013308081A1 (enExample)
CA (1) CA2882039A1 (enExample)
HK (1) HK1211916A1 (enExample)
IN (1) IN2015MN00421A (enExample)
WO (1) WO2014033604A1 (enExample)
ZA (1) ZA201501053B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882039A1 (en) 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
CA2920818A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
EP3538510B1 (en) * 2016-11-14 2021-01-06 Byondis B.V. Process for the preparation of mono-protected alpha,omega-diamino alkanes
CA3166210A1 (en) * 2019-12-27 2021-07-01 Lupin Limited Pharmaceutical composition of casr modulators and methods and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1147459C (zh) * 1994-10-21 2004-04-28 Nps药物有限公司 钙受体活性化合物
CN100558698C (zh) * 1994-10-21 2009-11-11 Nps药物有限公司 钙受体活性化合物
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
ATE452121T1 (de) * 2003-04-23 2010-01-15 Japan Tobacco Inc Casr-antagonist
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト
CA2608957C (en) 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
US9487494B2 (en) 2007-11-23 2016-11-08 Leo Pharma A/S Cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 CaSRアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
EP2643298A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
CA2828415A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2012127385A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
HRP20191606T1 (hr) * 2012-02-24 2019-12-13 Lupin Ltd Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij
CA2882039A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators

Also Published As

Publication number Publication date
US20150239827A1 (en) 2015-08-27
CN104583177B (zh) 2016-09-07
US9598371B2 (en) 2017-03-21
HK1211916A1 (en) 2016-06-03
JP2015528462A (ja) 2015-09-28
CN104583177A (zh) 2015-04-29
ZA201501053B (en) 2016-01-27
US9227919B2 (en) 2016-01-05
US20170137371A1 (en) 2017-05-18
EP2888225A1 (en) 2015-07-01
CA2882039A1 (en) 2014-03-06
AU2013308081A1 (en) 2015-02-26
WO2014033604A1 (en) 2014-03-06
US20160075655A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
IN2014MN01672A (enExample)
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
IN2014MN02126A (enExample)
PH12013501899A1 (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
MX2014003169A (es) Ligandos del receptor ep1.
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
PH12014501079A1 (en) 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2014MN02127A (enExample)
IN2015MN00421A (enExample)
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
AR083430A1 (es) Compuestos utiles como agentes terapeuticos para enfermedades, trastornos y condiciones que pueden tratarse inter alia por modulacion de receptores opiaceos, acetilcolinesterasa, receptores de nmda, y recaptacion de serotonina y/o norepinefrina; y composiciones farmaceuticas que comprenden tales compuestos
PH12014500934A1 (en) Nicotinic receptor non-competitive modulators